BMPR2 Mouse Monoclonal Antibody [Clone ID: 1F12]
CAT#: AM06596SU-N
BMPR2 mouse monoclonal antibody, clone 1F12, Ascites
Need it in bulk or conjugated?
Get a free quote
CNY 5,775.00
货期*
5周
规格
Specifications
Product Data | |
Clone Name | 1F12 |
Applications | ELISA, IHC, WB |
Recommend Dilution | ELISA: 1/10000. Western Blot: 1/500 - 1/2000. Immunohistochemistry on Paraffin Sections: 1/200 - 1/1000. |
Reactivity | Human, Monkey, Mouse, Rat |
Host | Mouse |
Clonality | Monoclonal |
Immunogen | Purified recombinant fragment of human BMPR2 expressed in E. Coli. |
Specificity | This antibody recognizes BMPR2 |
Formulation | State: Ascites State: Ascitic fluid containing 0.03% Sodium Azide. |
Conjugation | Unconjugated |
Storage Condition | Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. |
Predicted Protein Size | 115 kDa |
Gene Name | bone morphogenetic protein receptor type 2 |
Database Link | |
Background | This gene encodes a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of two different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in this gene have been associated with primary pulmonary hypertension, both familial and fenfluramine-associated, and with pulmonary venoocclusive disease. (provided by RefSeq) |
Synonyms | BMP type II receptor, BMPR-II, PPH1 |
Reference Data |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...